Overall rank by patents
#45,650
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
COUR Pharmaceuticals Development Company Inc.
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, active 2018–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
5
Total patents granted
5
CPC technology areas
18.8
Avg claims per patent
-33%
5-year filing velocity
The verdict
COUR holds 5 US patents across 5 technology areas, rank #45,650 of 50,000 tracked assignees.
- #45,650
- of 50,000 US assignees by volume
- Top 40%
- by Innovation Score (38.7/100)
- 18.8
- avg claims per patent
- -33%
- filing velocity, last 5 yrs
Portfolio overview
COUR Pharmaceuticals Development Company Inc. has been granted 5 US utility patents between 2018 and 2022, placing COUR Pharmaceuticals Development Company Inc. at rank #45,650 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.8 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, COUR Pharmaceuticals Development Company Inc. is one of the more focused assignees in the PatentsView dataset. By volume, COUR sits between Cosmed S.r.l. (5 patents, rank #45,646) and CPI CARD Group—tennessee, Inc. (5 patents, rank #45,654) - the closest US assignees by grant volume. The composite Innovation Score of 38.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 3 in the 2015–2019 window, a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. COUR Pharmaceuticals Development Company Inc.'s 18.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark COUR Pharmaceuticals Development Company Inc. against peers pursuing similar technology classes.
Who files at COUR's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cosmed S r l
COSMED S.r.l.
5 patents
- Cottonwood Creek
COTTONWOOD CREEK TECHNOLOGIES, INC.
5 patents
- Council OF Scient…
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860)
5 patents
- Country VIEW Medi…
COUNTRY VIEW MEDICAL CENTER
5 patents
- Coventya
COVENTYA GMBH
5 patents
- COX Engineering
COX ENGINEERING COMPANY
5 patents
- COX Goettl Valve
COX GOETTL VALVE LLC
5 patents
- CPI CARD Group—Te…
CPI CARD GROUP—TENNESSEE, INC.
5 patents
- COUR Pharmaceutic… ◀
COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC.
5 patents
What this shows COUR holds 5 patents at rank #45,650, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near COUR
By rank, the assignees closest to #45,650 in granted patent volume.
- Cosmed S.r.l. #45,646 · 5 patents
- Cottonwood Creek Technologies, Inc. #45,647 · 5 patents
- Council OF Scientific AND Industrial Research AN Indian Registered BODY Incorporated Under THE REGN. OF SOC. ACT (act XXI OF 1860) #45,648 · 5 patents
- Country VIEW Medical Center #45,649 · 5 patents
- Coventya Gmbh #45,651 · 5 patents
- COX Engineering Company #45,652 · 5 patents
- COX Goettl Valve Llc #45,653 · 5 patents
- CPI CARD Group—tennessee, Inc. #45,654 · 5 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in COUR's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
COUR's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
39 Top 40% higher than 60% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 2 | 40.0% |
| 2019 | 1 | 20.0% |
| 2022 | 2 | 40.0% |
Which technologies does COUR Pharmaceuticals Development Company Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does COUR Pharmaceuticals Development Company Inc. hold?
COUR Pharmaceuticals Development Company Inc. holds 5 US granted patents filed between 2018 and 2022, spanning 5 technology areas.
What is COUR Pharmaceuticals Development Company Inc.'s Innovation Score?
COUR Pharmaceuticals Development Company Inc. has an Innovation Score of 38.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does COUR Pharmaceuticals Development Company Inc. focus on?
COUR Pharmaceuticals Development Company Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 5 patents. The company has filed patents in 5 CPC subclasses total.
Is COUR Pharmaceuticals Development Company Inc.'s patent filing rate increasing or decreasing?
COUR Pharmaceuticals Development Company Inc.'s recent filing velocity is -33% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for COUR Pharmaceuticals Development Company Inc.'s patents?
COUR Pharmaceuticals Development Company Inc.'s patents average 18.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the COUR Pharmaceuticals Development Company Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
COUR's 5 grants land it in the top 40% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - COUR ranks #45,650 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.